Bellicum pharmaceuticals announces closing of $25.0 million underwritten offering

Houston, nov. 03, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing of its underwritten offering of 1,040,000 shares of common stock, pre-funded warrants to purchase 3,109,378 shares of common stock and accompanying warrants to purchase up to 4,149,378 shares of common stock. each share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.025 and each pre-funded warrant to purchase one share of common stock was sold together with a warrant to purchase one share of common stock at a combined offering price of $6.024. the exercise price of each pre-funded warrant is $0.001 per share and the exercise price of each accompanying warrant to purchase common stock is $6.50 per share.
BLCM Ratings Summary
BLCM Quant Ranking